| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yu C.-J.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; TZU-HSIU TSAI; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Su K.-Y.; Chang Y.-L.; Liu Y.-N.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yu C.-J.; Yang J.C.-H.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 國立成功大學 |
2020 |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de, Bono J.;Lin, C.-C.;Chen, L.-T.;Corral, J.;Michalarea, V.;Rihawi, K.;Ong, M.;Lee, J.-H.;Hsu, C.-H.;Yang, J.C.-H.;Shiah, H.-S.;Yen, C.-J.;Anthoney, Anthoney A.;Jove, M.;Buschke, S.;Fuertig, R.;Schmid, U.;Goeldner, R.-G.;Strelkowa, N.;Huang, D.C.-L.;Bogenrieder, T.;Twelves, C.;Cheng, A.-L. |
| 國立成功大學 |
2020 |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Yang, J.C.-H.;Camidge, D.R.;Yang, C.-T.;Zhou, J.;Guo, R.;Chiu, Chiu C.-H.;Chang, G.-C.;Shiah, H.-S.;Chen, Y.;Wang, C.-C.;Berz, D.;Su, W.-C.;Yang, N.;Wang, Z.;Fang, J.;Chen, J.;Nikolinakos, P.;Lu, Y.;Pan, H.;Maniam, A.;Bazhenova, L.;Shirai, K.;Jahanzeb, M.;Willis, M.;Masood, N.;Chowhan, N.;Hsia, T.-C.;Jian, H.;Lu, S. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Shih J.-Y.; WEI-YU LIAO; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Wei-Yu Liao;Shih J.-Y.;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Chen J.-S.; Lin Z.-Z. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; CHONG-JEN YU; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Shih J.-Y.;Chong-Jen Yu;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; JIN-YUAN SHIH; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Jin-Yuan Shih;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
| 臺大學術典藏 |
2018 |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Fu-Ren Xiao;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M.; Yang W.-C.; FU-REN XIAO; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2018 |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Wei-Yu Liao;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; WEI-YU LIAO; Lee J.-H.; Tsai T.-H. |
| 臺大學術典藏 |
2018 |
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
|
Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Liu Y.-N.; SHANG-GIN WU; Shang-Gin Wu;Liu Y.-N.;Yu C.-J.;Yang J.C.-H.;Shih J.-Y. |
| 國立成功大學 |
2018 |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Wu, Y.-L.;Zhang, L.;Kim, D.-W.;Liu, X.;Lee, D.H.;Yang, J.C.-H.;Ahn, M.-J.;Vansteenkiste, J.F.;Su, W.-C.;Felip, E.;Chia, V.;Glaser, S.;Pultar, Pultar P.;Zhao, S.;Peng, B.;Akimov, M.;Tan, D.S.W. |
| 臺大學術典藏 |
2017 |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Lin C.-C.; Lin Z.-Z.; Chen J.-S.; JIN-YUAN SHIH; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2017 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
Lin Y.-T.;Liu Y.-N.;Wu S.-G.;Yang J.C.-H.;Jin-Yuan Shih; Lin Y.-T.; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2017 |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Gautschi O.;Milia J.;Filleron T.;Wolf J.;Carbone D.P.;Owen D.;Camidge R.;Narayanan V.;Doebele R.C.;Besse B.;Remon-Masip J.;Janne P.A.;Awad M.M.;Peled N.;Byoung C.-C.;Karp D.D.;Van Den Heuvel M.;Wakelee H.A.;Neal J.W.;Mok T.S.K.;Yang J.C.H.;Ou S.-H.I.;Pall G.;Froesch P.;Zalcman G.;Gandara D.R.;Riess J.W.;Velcheti V.;Zeidler K.;Diebold J.;Fr?H M.;Michels S.;Monnet I.;Popat S.;Rosell R.;Karachaliou N.;Rothschild S.I.;Jin-Yuan Shih;Warth A.;Muley T.;Cabillic F.;Mazi?Res J.;Drilon A.; Michels S.; Monnet I.; Popat S.; Rosell R.; Karachaliou N.; Rothschild S.I.; JIN-YUAN SHIH; Warth A.; Muley T.; Cabillic F.; Mazi?res J.; Drilon A.; Gautschi O.; Milia J.; Filleron T.; Wolf J.; Carbone D.P.; Owen D.; Camidge R.; Narayanan V.; Doebele R.C.; Besse B.; Remon-Masip J.; Janne P.A.; Awad M.M.; Peled N.; Byoung C.-C.; Karp D.D.; Van Den Heuvel M.; Wakelee H.A.; Neal J.W.; Mok T.S.K.; Yang J.C.H.; Ou S.-H.I.; Pall G.; Froesch P.; Zalcman G.; Gandara D.R.; Riess J.W.; Velcheti V.; Zeidler K.; Diebold J.; Fr?h M. |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
